Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
16 déc. 2024 16h01 HE
|
Candel Therapeutics
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
Ear Infection Treatment Market to Reach $19.5 Billion, Globally, by 2032 at 5.1% CAGR: Allied Market Research
14 sept. 2023 04h05 HE
|
Allied Market Research
New Castle, Delaware, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Ear Infection Treatment Market by Infection (Inner Ear, Middle Ear, Outer Ear), By...
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB
28 juin 2023 09h00 HE
|
Sirona Biochem Corp.
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- June 28, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is excited to announce the development of a...
Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd
31 mai 2023 12h25 HE
|
Visiongain Reports Ltd
Visiongain has published a new report: Recombinant Proteins Market: Forecasts by Products & Services (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILS), Others), Antibodies,...
Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update
10 mai 2023 16h05 HE
|
Icosavax, Inc.
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term...
Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd
05 mai 2023 11h43 HE
|
Visiongain Reports Ltd
Visiongain has published a new report: Recombinant Proteins Market: Forecasts by Products & Services (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILS), Others), Antibodies,...
Recombinant proteins market is projected to grow at a CAGR of 11.14% by 2033: Visiongain Reports Ltd
20 avr. 2023 11h52 HE
|
Visiongain Reports Ltd
Visiongain has published a new report: Recombinant Proteins Market:- Forecasts by Products & Services (Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILS), Others), Antibodies,...
WellSpan Health and Helix announce partnership to improve patient health outcomes through new population genomics program
08 déc. 2022 08h50 HE
|
WellSpan Health
York, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- WellSpan Health and Helix, the nation’s leading population genomics and viral surveillance company, announced today a partnership to create a...
AB Science - Recommandation favorable du comité indépendant de revue des données de poursuivre l’étude de Phase 2 évaluant l’activité antivirale du masitinib dans le traitement du Covid-19
14 sept. 2022 12h21 HE
|
AB Science
COMMUNIQUE DE PRESSE RECOMMANDATION FAVORABLE DU COMITE INDEPENDANT DE REVUE DES DONNEES DE POURSUIVRE L’ETUDE DE PHASE 2 EVALUANT L’ACTIVITE ANTIVIRALE DU MASITINIB DANS LE TRAITEMENT DU COVID-19 ...
AB Science - Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19
14 sept. 2022 12h21 HE
|
AB Science
PRESS RELEASE POSITIVE RECOMMENDATION OF THE DATA AND SAFETY MONITORING BOARD TO CONTINUE THE PHASE 2 STUDY EVALUATING ANTIVIRAL ACTIVITY OF MASITINIB IN COVID-19 Paris, 14 September 2022,...